The purpose of Idorsia is to discover, develop and commercialize innovative medicines to help more patients.
Idorsia has raised $313.9M in total funding. The most recent round was Post-IPO Debt. The last funding was announced in June 2026.
Idorsia's investors include CARB-X, Pharmakon Advisors, Jean-Paul Clozel.
Idorsia is headquartered in Allschwil, Switzerland.
The purpose of Idorsia is to discover, develop and commercialize innovative medicines to help more patients.
Idorsia is at the Post-IPO Debt stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Idorsia — Funding & Investors." VCBacked, June 9, 2026, https://www.vcbacked.co/company/idorsia. Accessed August 22, 2026.
VCBacked. (2026). Idorsia — Funding & Investors. Retrieved August 22, 2026, from https://www.vcbacked.co/company/idorsia
{{cite web |title=Idorsia — Funding & Investors |url=https://www.vcbacked.co/company/idorsia |website=VCBacked |access-date=August 22, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated